(0)サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1304562

乳がん治療薬の世界市場-2023年～2030年

Global Breast Cancer Drugs Market Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
乳がん治療薬の世界市場-2023年～2030年
出版日: 2023年07月07日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

乳がん治療薬の世界市場は、2022年に287億米ドルに達し、2030年には571億米ドルに達する好成長が予測されています。乳がん治療薬の世界市場は、2023～2030年の予測期間中にCAGR 9.2%を示すと予測されます。新規治療法の発見と既存治療法の最適化に対する需要の増加が、乳がん治療薬市場の動向を押し上げています。

乳がん治療薬市場は著しい成長を遂げており、今後も拡大が続くと予想されます。乳がんに対する意識の高まり、検診プログラムの改善、早期発見への取り組みが診断率の上昇につながっており、それによって乳がん治療薬を含む効果的な治療オプションに対する需要が増加しています。

さらに、ゲノム・プロファイリングや個別化医療アプローチの進歩が標的療法の市場開拓を後押ししており、従来の化学療法と比較して有効性が向上し、副作用が軽減されることから、市場で脚光を浴びています。

市場力学

技術革新と新薬承認に対する需要の増加が乳がん治療薬市場の成長を牽引

乳がん患者の増加に伴い、世界的に最も一般的で生命を脅かす可能性のあるがんの1つである乳がんと闘うため、より効果的で的を絞った治療法が継続的に必要とされています。その結果、製薬会社は新薬や治療アプローチを導入するための研究開発に多額の投資を行っています。

例えば、Gilead Sciences社は2023年02月03日、米国食品医薬品局（FDA）が乳がん治療薬としてトロデルヴィ（サシツズマブ・ゴビテカン-hziy）を承認したと発表し、トロデルヴィは現在、腫瘍学の臨床診療ガイドライン（NCCNガイドライン）で定義された全米総合がんネットワーク（NCCN）によって、転移性HR+/HER2-乳がんに対するカテゴリー1の優先治療薬としても推奨されていると発表しました。

市場成長の原動力は、患者の転帰とQOLを改善する革新的なソリューションの追求です。分子生物学、ゲノミクス、個別化医療の進歩により、乳がん細胞における特定の分子標的や経路が発見されるようになっています。この知識は、これらの標的に選択的に作用し、より正確で効果的な治療を提供する標的療法の開発への道を強化しました。

意識の高まりと早期発見も乳がん治療薬市場の成長を促進する

乳がんに対する意識が高まるにつれて、定期的な検診を受け、兆候や症状が現れたらすぐに医療機関を受診するよう奨励される人が増えています。早期発見はタイムリーな診断を可能にし、治療成績の向上と生存率の上昇につながります。早期発見される乳がん症例が増えるにつれて、乳がん治療薬を含む効果的な治療オプションに対する需要も高まっています。

例えば、 Adani Cementsのセメント建材会社でAdani Groupの一員であるAmbuja Cementsは、CSR部門を通じて2023年4月3日、マハラシュトラ州チャンドラプールで、英国乳腺外科学会（ABS）、インド乳腺外科学会（ABSI）、タタ・キャンサー・ケア・プログラムと共同で、地域社会を教育するためのがん啓発・教育プログラムを開始しました。

早期発見の重視は、医療画像技術や診断技術の進歩によって支えられています。マンモグラフィ、超音波検査、磁気共鳴画像法（MRI）などの検診方法の向上により、乳がんが局在化し、治療しやすい早期段階で発見できるようになっています。この早期発見へのシフトは、患者の予後を改善するだけでなく、乳がん治療薬を含む適切な治療薬への需要も促進します。

薬剤コストの高さが市場成長を妨げる

乳がん治療薬の高額な費用は、特に十分な保険が適用されない患者や経済的に余裕のない患者にとって、経済的な問題を引き起こす可能性があります。これらの薬剤に関連する自己負担額は負担となり、人口のかなりの部分が薬剤にアクセスできなくなる可能性があります。手ごろな価格の乳がん治療薬へのアクセスが限られていると、治療のアドヒアランスや患者の転帰に影響を及ぼし、市場成長の妨げとなる可能性があります。

ヘルスケアシステムと支払者は、乳がん治療薬の高額な費用を管理する上で課題に直面しています。ヘルスケアシステムの予算上の制約は、償還制限、処方制限、価格交渉などのコスト抑制策につながる可能性があります。こうした措置は市場力学に影響を与え、高価な薬剤の利用を制限するため、市場の成長を阻害する可能性があります。

COVID-19の影響分析

COVID-19の大流行は乳がん治療薬市場に大きな影響を与えました。この大流行により、COVID-19症例の管理にヘルスケア資源と注意が向けられるようになり、乳がん検診、診断、治療などの日常的なヘルスケアサービスに混乱が生じた。がんの手術や治療など、緊急性を要しない医療処置の多くが遅延または延期され、乳がん治療薬の需要全体に影響を及ぼしました。

乳がん治療薬の臨床試験はパンデミックの影響を大きく受けた。患者の安全を確保し、感染対策を遵守するために、多くの臨床試験が一時停止、延期、変更されました。臨床試験活動の鈍化は、医薬品開発の進展や新治療法の市場導入の妨げとなっています。

ロシア・ウクライナ紛争の影響分析

ロシアとウクライナの紛争は、世界の乳がん治療薬市場に中程度の影響を与えると推定されます。ロシアとウクライナの研究者、研究開発機関、患者が参加する共同研究は混乱に直面し、乳がん新薬開発の遅れにつながり、世界の市場拡大が制限されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • イノベーションと新薬承認に対する需要の増加
      • 意識の高まりと早期発見
    • 抑制要因
      • 薬剤費の高騰
    • 機会
      • 乳がん治療薬の技術的進歩
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 がんタイプ別

  • 転移性乳がん
  • トリプルネガティブ乳がん
  • 炎症性乳がん
  • その他

第8章 治療法別

  • 標的療法
  • 化学療法
  • 免疫療法
  • ホルモン療法
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Novartis AG
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • F. Hoffmann-La Roche Ltd.
  • AbbVie, Inc.
  • Eli Lilly and Company
  • AstraZeneca
  • Merck & Co., Inc.
  • Biocon Genzyme Corporation
  • MacroGenics Inc.
  • Janssen Global Services LLC
  • Onyx Pharmaceuticals Inc.

第13章 付録

目次
Product Code: PH916

Market Overview

The Global Breast Cancer Drugs Market reached US$ 28.7 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 57.1 billion by 2030. The Global Breast Cancer Drugs Market is expected to exhibit a CAGR of 9.2% during the forecast period 2023-2030. The increasing demand for discovering novel therapies and optimizing existing treatments are driving up demand for breast cancer drug market trends.

The Breast cancer drugs market is witnessing significant growth and is expected to continue expanding in the coming years. The rising awareness about breast cancer, improved screening programs, and early detection initiatives are leading to higher diagnosis rates, thereby increasing the demand for effective treatment options, including breast cancer drugs.

Additionally, advancements in genomic profiling and personalized medicine approaches are driving the development of targeted therapies, which are gaining prominence in the market due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy.

Market Dynamics

Increasing Demand for Innovations and New Drug Approvals Drive the Growth of the Breast Cancer Drugs Market

As the number of breast cancer patients rises, there is a continuous need for more effective and targeted therapies to combat breast cancer, one of the most common and potentially life-threatening cancers worldwide. As a result, pharmaceutical companies are investing heavily in research and development to introduce novel drugs and treatment approaches.

For instance, on February 03, 2023, Gilead Sciences, Inc. announced the U.S. Food and Drug Administration (FDA) approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of breast cancer and announced that the Trodelvy is now also recommended as a Category 1, preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network (NCCN) as defined in the Clinical Practice Guidelines in Oncology (NCCN Guidelines)

The market's growth is fueled by the pursuit of innovative solutions that can improve patient outcomes and quality of life. Advances in molecular biology, genomics, and personalized medicine have led to the discovery of specific molecular targets and pathways in breast cancer cells. This knowledge enhanced the way for the development of targeted therapies that selectively act on these targets, delivering more precise and effective treatments.

Rising Awareness and Early Detection Also Drive the Growth of the Breast Cancer Drugs Market

As awareness about breast cancer grows, more individuals are encouraged to undergo regular screenings and seek medical attention at the earliest signs or symptoms. Early detection enables timely diagnosis, which leads to improved treatment outcomes and increased survival rates. With a larger number of breast cancer cases being detected in the early stages, the demand for effective treatment options, including breast cancer drugs, rises.

For instance, on April 03, 2023, Ambuja Cements, the cement and building material company of Adani Cement and part of Adani Group, through its CSR arm launched a Cancer Awareness and Education program in collaboration with the Association of Breast Surgery (ABS), UK along with its counterpart Association of Breast Surgeons in India (ABSI) and Tata Cancer Care Program, in Chandrapur, Maharashtra to educate communities.

The emphasis on early detection is supported by advancements in medical imaging technologies and diagnostic techniques. Improved screening methods, such as mammography, ultrasound, and magnetic resonance imaging (MRI), enable the identification of breast cancer at earlier stages when the disease is localized and more amenable to treatment. This shift towards early detection not only improves patient outcomes but also drives the demand for appropriate therapies, including breast cancer drugs.

The High Cost of Drugs will Hamper the Growth of the Market.

The high cost of breast cancer drugs can create affordability issues for patients, particularly those without adequate insurance coverage or limited financial resources. The out-of-pocket expenses associated with these drugs can be burdensome, making them inaccessible to a significant portion of the population. Limited access to affordable breast cancer drugs can impact treatment adherence and patient outcomes, thereby hampering market growth.

Healthcare systems and payers face challenges in managing the high costs of breast cancer drugs. The budgetary constraints of healthcare systems can lead to cost containment measures, including reimbursement limitations, formulary restrictions, and price negotiations. These measures can affect the market dynamics and limit the utilization of expensive drugs, thus impeding market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the Breast Cancer Drugs Market. The pandemic led to a diversion of healthcare resources and attention towards managing COVID-19 cases, resulting in disruptions in routine healthcare services, including breast cancer screenings, diagnosis, and treatment. Many non-urgent medical procedures, including cancer surgeries and treatments, were delayed or postponed, affecting the overall demand for breast cancer drugs.

Clinical trials for breast cancer drugs were significantly affected by the pandemic. Many trials were paused, delayed, or modified to ensure patient safety and comply with infection control measures. The slowdown in clinical trial activities hindered the progress of drug development and the introduction of new therapies into the market.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to impact the Global Breast Cancer Drugs market moderately. The conflict may affect international collaborations in clinical trials and research efforts t. Collaborative studies involving researchers, institutions, and patients from Russia and Ukraine faced disruptions, leading to delays in developing new breast cancer drugs and limiting the expansion of the market globally.

Segment Analysis

The Global Breast Cancer Drugs Market is segmented based on cancer type, therapy, distribution channel, and region.

Targeted Therapy from the Therapy Segment Accounts for 47.4% of the Breast Cancer Drugs Market Share

Targeted therapy specifically focuses on cancer cells by identifying and attacking specific molecular targets involved in the growth and spread of cancer. Compared to traditional chemotherapy, targeted therapies offer the potential for more effective and precise treatments with reduced toxicity and side effects.

Targeted therapy drugs are designed to inhibit or block specific proteins or pathways crucial for cancer cells' growth and survival. These drugs can be classified into various categories, including monoclonal antibodies, tyrosine kinase inhibitors, hormone receptor blockers, and poly (ADP-ribose) polymerase (PARP) inhibitors. They are often used in combination with other treatment modalities, such as chemotherapy or radiation therapy, to enhance the overall effectiveness of the treatment.

For instance, on August 05, 2022, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer. This is the first approved targeted therapy for patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.

Geographical Analysis

North America Accounted for Approximately 39.8% of the Market Share in 2022, Owing to the Favourable Reimbursement Policies and Advanced Healthcare Infrastructure.

North America, particularly the United States, benefits from a well-established healthcare system with advanced medical facilities, leading research institutions, and a robust pharmaceutical industry. The region has a strong focus on cancer research and development, leading to the availability of a wide range of breast cancer drugs. The advanced healthcare infrastructure ensures timely diagnosis, access to advanced treatment options, and comprehensive care for breast cancer patients.

Moreover, favorable reimbursement policies in North America contribute to the growth of the market. Adequate reimbursement for breast cancer drugs enables patients to access these treatments without significant financial burden. Health insurance coverage, both public and private, plays a crucial role in facilitating patient access to expensive cancer drugs, ensuring a larger patient population can benefit from the available treatment options.

Competitive Landscape

The major global players in the breast cancer drugs market include: Novartis AG, F. Hoffmann-La Roche Ltd., AbbVie, Inc., Eli Lilly and Company, AstraZeneca, Merck & Co., Inc., Biocon Genzyme Corporation, MacroGenics, Inc., Janssen Global Services LLC, and Onyx Pharmaceuticals Inc.

Why Purchase the Report?

  • To visualize the Global Breast Cancer Drugs Market segmentation based on cancer type, therapy, distribution channel, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of breast cancer drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Breast Cancer Drugs Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Therapy
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Innovations and New Drug Approvals
      • 4.1.1.2. Rising Awareness and Early Detection
    • 4.1.2. Restraints
      • 4.1.2.1. The High Cost of Drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological Advancements in Breast Cancer Drugs
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type
  • 7.2. Metastatic Breast Cancer *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Triple Negative Breast Cancer
  • 7.4. Inflammatory Breast Cancer
  • 7.5. Others

8. By Therapy

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 8.1.2. Market Attractiveness Index, By Therapy
  • 8.2. Targeted Therapy *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Chemotherapy
  • 8.4. Immunotherapy
  • 8.5. Hormonal Therapy
  • 8.6. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Novartis AG *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. F. Hoffmann-La Roche Ltd.
  • 12.3. AbbVie, Inc.
  • 12.4. Eli Lilly and Company
  • 12.5. AstraZeneca
  • 12.6. Merck & Co., Inc.
  • 12.7. Biocon Genzyme Corporation
  • 12.8. MacroGenics Inc.
  • 12.9. Janssen Global Services LLC
  • 12.10. Onyx Pharmaceuticals Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us